Patents by Inventor Andras Toro

Andras Toro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IRE-1? inhibitors
    Patent number: 11337956
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: May 24, 2022
    Assignee: Fosun Orinove Pharmatech, Inc.
    Inventors: Qingping Zeng, Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
  • IRE-1ALPHA INHIBITORS
    Publication number: 20190314330
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Application
    Filed: June 3, 2019
    Publication date: October 17, 2019
    Inventors: Qingping ZENG, Andras TORO, John Bruce PATTERSON, Warren Stanfield WADE, Zoltan ZUBOVICS, Yun YANG, Zhipeng WU
  • IRE-1? inhibitors
    Patent number: 10357475
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: July 23, 2019
    Assignee: Fosun Orinove PharmaTech, Inc.
    Inventors: Qingping Zeng, Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
  • IRE-1ALPHA INHIBITORS
    Publication number: 20180228765
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Application
    Filed: December 8, 2017
    Publication date: August 16, 2018
    Inventors: Qingping Zeng, Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
  • IRE-1? inhibitors
    Patent number: 9867803
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: January 16, 2018
    Assignee: SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD.
    Inventors: Qingping Zeng, Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
  • IRE-1ALPHA INHIBITORS
    Publication number: 20170326104
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Application
    Filed: May 19, 2017
    Publication date: November 16, 2017
    Inventors: Qingping Zeng, Jr., Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
  • IRE-1? inhibitors
    Patent number: 9693992
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: July 4, 2017
    Assignee: MannKind Corporation
    Inventors: Qingping Zeng, Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
  • IRE-1? inhibitors
    Patent number: 9040714
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts there-of. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: May 26, 2015
    Assignee: MannKind Corporation
    Inventors: Qingping Zeng, Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
  • IRE-1alpha INHIBITORS
    Publication number: 20150141424
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 21, 2015
    Inventors: Qingping ZENG, Andras TORO, John Bruce PATTERSON, Warren Stanfield WADE, Zoltan ZUBOVICS, Yun YANG, Zhipeng WU
  • Acrylamide derivatives as Fab I inhibitors
    Patent number: 8895545
    Abstract: In part, the present invention is directed to antibacterial compounds.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: November 25, 2014
    Assignee: Debiopharm International SA
    Inventors: Heinz W. Pauls, Jailall Ramnauth, Peter Sampson, Andras Toro
  • ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS
    Publication number: 20130237523
    Abstract: In part, the present invention is directed to antibacterial compounds.
    Type: Application
    Filed: October 4, 2012
    Publication date: September 12, 2013
    Applicant: AFFINIUM PHARMACEUTICALS, INC.
    Inventors: Heinz W. Pauls, Jailall Ramnauth, Peter Sampson, Andras Toro
  • Therapeutic agents, and methods of making and using the same
    Patent number: 8450307
    Abstract: In part, the present invention is directed to antibacterial compounds.
    Type: Grant
    Filed: June 6, 2005
    Date of Patent: May 28, 2013
    Assignee: Affinium Pharmaceuticals, Inc.
    Inventors: Bruce J. Sargent, Henry Pauls, Judd M. Berman, Jailall Ramnauth, Peter Sampson, Andras Toro, Fernando J. Martin, Matthew D. Surman, Helene Y. Decornez, David D. Manning
  • IRE-1alpha INHIBITORS
    Publication number: 20130116247
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts there-of. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Application
    Filed: April 5, 2011
    Publication date: May 9, 2013
    Applicant: MANNKIND CORPORATION
    Inventors: Qingping Zeng, Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
  • Acrylamide derivatives as Fab I inhibitors
    Patent number: 8318720
    Abstract: In part, the present invention is directed to antibacterial compounds.
    Type: Grant
    Filed: July 19, 2007
    Date of Patent: November 27, 2012
    Assignee: Affinium Pharmaceuticals, Inc.
    Inventors: Heinz W. Pauls, Jailall Ramnauth, Peter Sampson, Andras Toro
  • ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS
    Publication number: 20100130470
    Abstract: In part, the present invention is directed to antibacterial compounds.
    Type: Application
    Filed: July 19, 2007
    Publication date: May 27, 2010
    Inventors: Heinz W. Pauls, Jailall Ramnauth, Peter Sampson, Andras Toro
  • Therapeutic agents, and methods of making and using the same
    Publication number: 20100093705
    Abstract: In part, the present invention is directed to antibacterial compounds.
    Type: Application
    Filed: June 6, 2005
    Publication date: April 15, 2010
    Inventors: Bruce J. Sargent, Henry Pauls, Judd M. Berman, Jailall Ramnauth, Peter Sampson, Andras Toro, Fernando J. Martin, Matthew D. Surman, Helene Y. Decornez, David D. Manning
  • COMPOUNDS AND METHODS OF USE
    Publication number: 20090048224
    Abstract: Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: September 5, 2008
    Publication date: February 19, 2009
    Applicants: Amgen, Inc., Array BioPharma, Inc.
    Inventors: Robert D. Groneberg, Benny C. Askew, JR., Derin C. D'Amico, James Zhan, Andras Toro, Youngboo Kim, David A. Mareska, Nianhe Han, Christopher H. Fotsch, Qingyian Liu, Babak Riahi, Kevin Yang, Aiwen Li, Chester Chenguang Yuan, Kaustav Biswas, Scott Harried, Thomas Nguyen, Wenyuan Qian, Jian Jeffrey Chen, Rana Nomak
  • Compounds and methods of use
    Patent number: 7425631
    Abstract: Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: September 16, 2008
    Assignees: Amgen Inc., Array BioPharma Inc.
    Inventors: Robert D. Groneberg, Benny C. Askew, Jr., Derin C. D'Amico, James Zhan, Andras Toro, Youngboo Kim, David A. Mareska, Nianhe Han, Christopher H. Fotsch, Qingyian Liu, Babak Riahi, Kevin Yang, Aiwen Li, Chester Chenguang Yuan, Kaustav Biswas, Scott Harried, Thomas Nguyen, Wenyuan Qian, Jian Jeffrey Chen, Rana Nomak
  • Compounds and methods of use
    Publication number: 20050124654
    Abstract: Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: April 12, 2004
    Publication date: June 9, 2005
    Inventors: Robert Groneberg, Bonny Askew, Derin D'Amico, James Zhan, Andras Toro, Youngboo Kim, David Mareska, Nianhe Han, Christopher Fotsch, Qingyian Liu, Babak Riahi, Kevin Yang, Aiwen Li, Chester Yuan, Kaustav Biswas, Scott Harried, Thomas Nguyen, Wenyuan Qian, Jian Chen, Rana Nomak
  • Process for the preparation of steroids bearing 17.alpha.-hydroxy-20-oxopregnane side chain
    Patent number: 5241063
    Abstract: The invention relates to a novel process for the preparation of 17 .alpha.-hydroxy-20-oxopregnane derivatives of the general formula (I), ##STR1## wherein R.sub.1 means a hydroxy or an oxo group; andthe dotted lines optionally represent one or more additional valence bond(s), with the proviso that the dotted line in the 4-position and the dotted line in the 5-position cannot each simultaneously be an additional valence bond from steroids having 23,24-dinor-17(20)-dehydrocholan-22-oic -22-oic acid structure.According to the process of the invention a steroid derivative having 23,24-dinorcholan-22-oic acid structure, containing a double bond in 17(20)-position, is transformed to 17.alpha., 20-epoxy-23,24-dinorcholanoic acid, the latter is converted to a reactive acid derivative, which is then reacted with a salt-containing azide ion to yield a 17.alpha., 20-epoxy-23,24-dinorcholanoic acyl azide derivative and the azide obtained is reacted with a mineral or organic acid in an aqueous medium.
    Type: Grant
    Filed: June 19, 1991
    Date of Patent: August 31, 1993
    Assignee: Richter Gedeon Vegyeszeti Gyar Rt.
    Inventors: Andras Toro, Gabor Ambrus, Istvan Pallagi, Nandor Makk, Gyula Horvath, Ferenc Szederkenyi, Eva Ilkoy, Antonia Jekkel, Imre Moravcsik, Kalman Konczol